Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Nicholas C. Turner(Institute of Cancer Research), Massimo Cristofanilli(Cornell University), Hiroji Iwata(Aichi Cancer Center), Sherene Loi(The University of Melbourne), Dennis J. Slamon(University of California, Los Angeles), Igor Bondarenko(Dnipro State Medical University), Nadia Harbeck(Breast Center), Cynthia Huang Bartlett(Pfizer (United States)), Marco Colleoni(European Institute of Oncology), Norikazu Masuda(Kyoto University), Seock‐Ah Im(Seoul National University), Xin Huang(Lineage Cell Therapeutics (United States)), C. Giorgetti(Kyiv City Clinical Oncology Center), Sibylle Loibl(Goethe University Frankfurt), Sunil Verma(VA Boston Healthcare System), Jungsil Ro(Western University), Fabrice André(Inserm), Kathy Puyana Theall(Pfizer (United States)), Angela DeMichele(University of Pennsylvania)
New England Journal of Medicine
October 20, 2018
10.1056/nejmoa1810527
Cited by 1,291

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k